Investments, Funding & Disinvestment

The government has fully funded the first phase of the vaccine manufacturing facility, which has already reached completion.

The program will also work to increase access to chemotherapy and provide essential emotional support services for patients navigating their cancer journey.

This acquisition expands Fullerton Health’s network of high-quality specialist care throughout Southeast Asia.

Environmental sustainability stands as a cornerstone of the 2024 report, with the company achieving a 58% reduction in diesel consumption and a 64% decrease in refrigerant gas usage.

The continued partnership aims to strengthen research focused on developing effective therapeutic options for mpox, a viral disease that currently lacks a dedicated antiviral treatment.

The sale came about following an unsolicited offer from BGH Capital, which focuses on investments in Australia and New Zealand.

The deal collapsed after STAAR failed to secure sufficient shareholder approval during a special stockholders meeting held on January 6.

This approach will help ensure that the local manufacturing of diagnostic imaging equipment remains economically viable and financially sustainable over the coming years.

Amgen’s latest acquisition is centered on Dark Blue’s lead candidate, DBT 3757, which specifically treats acute myeloid leukemia that affects bone marrow and blood cells.

Antimicrobial resistance (AMR) develops when bacteria, viruses, and fungi evolve to resist medications, making infections harder to treat and increasing the risk of severe illness and death.